Correctly folded etanercept in high purity and excellent yield

• US 10,947,306 B2
• Filed: 06/17/2019
• Issued: 03/16/2021
• Est. Priority Date: 09/11/2012
• Status: Active Grant

• Current Assignee: Coherus BioSciences Inc.
• Original Assignee: Coherus BioSciences Inc.
• Inventors: Arakawa, Tsutomu, Farrar, Douglas
• Primary Examiner(s): D'Ambrosio, Thea
• Application Number:
  US16/443,688
• Publication Number:
  US 20190330325A1
• Time in Patent Office: 638 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 1/165 mixed-mode chromatography
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.

Claims

1. A method of reducing incorrectly folded etanercept in and stabilizing an aqueous injectable pharmaceutical formulation containing about 25 to about 75 mg/ml correctly-folded etanercept, comprising:

a) removing incorrectly folded and aggregated etanercept from an etanercept-containing protein mixture using a mixed-mode chromatography procedure configured to produce an etanercept-containing composition such that the amount of said incorrectly folded etanercept is less than 5 wt % of said composition and wherein the amount of said correctly folded etanercept is greater than 95 wt %, wherein said incorrectly folded etanercept is an etanercept protein that has a conformation different from that of the correctly folded etanercept and said different conformation renders said incorrectly folded etanercept protein lacking in biological activity as a TNF inhibitor and said incorrectly folded etanercept is not an aggregate, wherein said mixed-mode chromatography procedure comprises binding correctly folded etanercept and incorrectly folded etanercept to a mixed-mode chromatography resin having both ion exchange and hydrophobic moieties and contacting the mixed-mode chromatography resin to elute with a salt solution at a pH between 4.5 and 8.5; and

b) combining the etanercept-containing composition formed in step (a) with a correctly folded etanercept-stabilizing formulation comprising about 0.1 to about 2 weight percent of a combination of sugar and an amino acid wherein the amino acid is not arginine and is not cysteine, 0 to about 25 mM NaCl, and an aqueous buffer selected from the group consisting of phosphate, histidine, citrate, maleate, tartrate, acetate, tris-(hydroxymethyl)-aminomethane (tris), and bicarbonate to form the aqueous injectable pharmaceutical formulation containing about 25 to about 75 mg/ml etanercept,

wherein the aqueous injectable pharmaceutical formulation has a pH of about 6.2 to 7.4 and does not contain cysteine and does not contain arginine, and

wherein the correctly folded etanercept-stabilizing formulation stabilizes said correctly-folded etanercept in said etanercept-containing composition such that the aqueous injectable pharmaceutical formulation is less immunogenic than a commercially available etanercept-containing composition and contains less incorrectly folded etanercept than a commercially available etanercept-containing composition.

2. The method of claim 1, wherein the aqueous injectable pharmaceutical formulation comprises about 0.1 to about 2 wt % of a combination of sucrose with alanine, glycine, or lysine;

and about 10 mM to about 200 mM of one or more tonicity modifiers selected from potassium chloride, sodium sulfate, and sodium citrate.

3. The method of claim 1, wherein less than 3 wt % of the etanercept in the etanercept-containing composition is incorrectly folded etanercept.

4. The method of claim 1, wherein less than 1 wt % of the etanercept in the etanercept-containing composition is incorrectly folded etanercept.

5. The method of claim 1, wherein less than 5 wt % of the etanercept in the etanercept-containing composition is incorrectly folded etanercept, fragments of etanercept, and aggregated etanercept.

6. The method of claim 1, wherein the aqueous injectable pharmaceutical formulation further comprises sodium citrate.

7. The method of claim 6, wherein the aqueous injectable pharmaceutical formulation comprises about 10 mM to about 200 mM of the sodium citrate.

8. The method of claim 1, wherein the aqueous injectable pharmaceutical formulation comprises about 0.1 to about 2 wt % of a combination of sucrose and lysine, and about 25 mM sodium chloride.

9. The method of claim 8, wherein the aqueous injectable pharmaceutical formulation does not contain any amino acid other than lysine.

10. The method of claim 9, wherein the aqueous buffer is citrate buffer.

11. The method of claim 1, wherein the eluting step comprises a NaCl gradient ranging from 0 to 0.5M NaCl and/or a pH gradient in a range of pH 4.5 and pH 8.

12. The method of claim 1, wherein the eluting step comprises a NaCl gradient ranging from 0 to 0.25M NaCl and an arginine gradient ranging from 0 to 0.5M arginine.

13. The method of claim 1, wherein hydrophobic interaction chromatography (HIC) is not used to separate said incorrectly folded etanercept from said correctly folded etanercept.

14. A method of treating a tumor necrosis factor (TNF) mediated disease in a patient comprising administering to said patient the aqueous injectable pharmaceutical formulation prepared according to claim 1.

15. The method of claim 14, comprising administering 25-100 mg etanercept per dose to the subject.

16. The method of claim 14, comprising injecting the aqueous injectable pharmaceutical formulation subcutaneously or intramuscularly.

17. The method of claim 14, wherein less than 3 wt % of the etanercept in the etanercept-containing composition is incorrectly folded etanercept.

18. A method of treating a subject in need of treatment for rheumatoid arthritis, psoriatic arthritis ankylosing spondylitis, Crohn'"'"'s disease, chronic obstructive pulmonary disease (COPD), asthma, or atopic dermatitis comprising administering to the subject the aqueous injectable pharmaceutical formulation prepared according to claim 1.

19. The method of claim 18, comprising administering 25-100 mg etanercept per dose to the subject.

20. The method of claim 19, wherein the administering comprises injecting the aqueous etanercept composition subcutaneously or intramuscularly.

21. A vial, syringe, or injector pen containing the aqueous injectable pharmaceutical formulation prepared according to claim 1.

22. The vial, syringe, or injector pen of claim 21, wherein less than 3 wt % of the etanercept in the etanercept-containing composition is incorrectly folded etanercept.